4
Changes in Ownership
Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000110
General Counsel sold 9,000 shares at an average $78.53 ($706,735)
- General Counsel acquired 9,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Quinlan Paul T General Counsel | 2026-10-20 | Option exercise 10b5-1 | +9,000 | $7.80 | $70,200 | 38,995 | D: show line 1 in the form |
| Quinlan Paul T General Counsel | 2026-10-20 | Sale 10b5-1 | −400 | $74.90 | $29,960 | 38,595 | D: show line 2 in the form |
| Quinlan Paul T General Counsel | 2026-10-20 | Sale 10b5-1 | −500 | $76.12 | $38,059 | 38,095 | D: show line 3 in the form |
| Quinlan Paul T General Counsel | 2026-10-20 | Sale 10b5-1 | −1,000 | $77.21 | $77,205 | 37,095 | D: show line 4 in the form |
| Quinlan Paul T General Counsel | 2026-10-20 | Sale 10b5-1 | −4,100 | $78.79 | $323,037 | 32,995 | D: show line 5 in the form |
| Quinlan Paul T General Counsel | 2026-10-20 | Sale 10b5-1 | −3,000 | $79.49 | $238,474 | 29,995 | D: show line 6 in the form |
| Open-market sales · 9,000 sh · avg $78.53 · $706,735 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Quinlan Paul T General Counsel | 2026-10-20 | Option exercise · Employee Warrant (right to buy) 10b5-1 | −9,000 | 70,996 | D: show line 7 in the form |
Loading xslF345X06/form4.xml…